A Phase 3 interventional study of BAX 326 (Recombinant factor IX) in Hemophilia B, sponsored by Baxalta now part of Shire. Completed at 42 sites in 17 countries. Open to participants aged Up to 65 Years. Per ClinicalTrials.gov, last updated 2021-05-20.
Sponsored by Baxalta now part of Shire · Phase 3, Interventional, and Treatment
The purpose of this BAX 326 Continuation Study is to further investigate incremental recovery over time, the hemostatic efficacy, the safety, immunogenicity, and health-related quality of life (HR QoL) of BAX 326 in previously treated patients (PTPs) with severe and moderately severe hemophilia B who participated in BAX 326 pivotal study 250901 or BAX 326 pediatric study 251101.
866 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
This study's enrollment of 117 is above the median of 28 across 512 interventional studies indexed under Hemophilia A.
Browse Hemophilia A studies →Baxalta now part of Shire is the lead sponsor of 110 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Biological: BAX 326 (Recombinant factor IX)
The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
Adverse Events Possibly or Probably Related to the Investigational Product
Possibly or probably related adverse events that occurred during or after first BAX326 infusion.
Time frame: Assessed (based on patient diary) every 3 months until study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Treatment of Bleeding Episodes: Number of Infusions Per Bleeding Episode Required Until Bleed Resolution
Number of Infusions of BAX326 that were required until bleed resolution.
Time frame: Throughout the study from screening to study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Treatment of Bleeding Episodes: Overall Hemostatic Efficacy Rating at Resolution of Bleed
Overall clinical efficacy rating of bleeding episodes was done at resolution of bleed according these rating scale: Excellent=Full relief of pain and cessation of objective signs of bleeding after a single infusion. No additional infusion is required for the control of bleeding. Administration of further infusion would not affect the scoring. Good=Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. Fair=Probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion. Required more than 1 infusion for complete resolution. None=No improvement or condition worsens.
Time frame: Throughout the study from screening to study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Annualized Bleed Rate During Prophylaxis Treatment
Annualized bleed rate (ABR) was calculated as (number of bleeding episodes/observed treatment period in days)\*365.25
Time frame: For prophylactic treatment the period from first to last prophylactic infusion is considered.
Consumption of BAX 326: Number of Infusions Per Month and Per Year
The number of infusions consumed per month and per year for the prophylactic and on-demand treatment regimens.
Time frame: Throughout the study from screening to study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Consumption of BAX 326: Weight Adjusted Consumption Per Month and Per Year
The weight adjusted consumption of BAX 326 per month and per year for the prophylactic and on-demand treatment regimens.
Time frame: Throughout the study from screening to study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Consumption of BAX326: Weight Adjusted Consumption Per Bleeding Episode
The weight adjusted consumption of BAX 326 per bleeding episode for the prophylactic and on-demand treatment regimens. Only infusions required until the resolution of bleed are considered.
Time frame: Throughout the study from screening to study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Development of Inhibitory and Total Binding Antibodies to Factor IX
Testing for inhibitory and total binding antibodies to Factor IX (FIX). Development during study means negative at screening and positive at any subsequent visit. Treatment emergent means more than 2-dilution increase as compared to the pre-study titer at screening.
Time frame: Laboratory assessment for immunology were done at screening, at exposure day 1, at week 4 (± 1 week), at month 3 (±1 week), thereafter, every 3 months (± 1 week) and at study completion/termination.
Development of Antibodies to Chinese Hamster Ovary Proteins (CHO Proteins) and rFurin
Testing for antibodies to CHO proteins and rFurin. Development during study means negative at screening and positive at any subsequent visit. Treatment emergent means more than 2-dilution increase as compared to the pre-study titer at screening.
Time frame: Laboratory assessment for immunology were done at screening, at exposure day 1, at week 4 (± 1 week), at month 3 (±1 week), thereafter, every 3 months (± 1 week) and at study completion/termination.
Occurrence of Severe Allergic Reactions and Thrombotic Events
The occurrence of severe allergic reactions and thrombotic events was assessed.
Time frame: Throughout the study from screening to study completion (when BAX326 is licensed in the respective country or the participant has accumulated approximately 100 exposure days to BAX 326, whichever is last).
Clinical Significant Changes in Routine Laboratory Parameters and Vital Signs
Hematology panel consists of complete blood count (hemoglobin, hematocrit, erythrocytes, leukocytes) with differential (ie, basophils, eosinophils, lymphocytes, monocytes, neutrophils), mean corpuscular volume, mean corpuscular hemoglobin concentration and platelet count. Clinical chemistry panel consists of sodium, potassium, chloride, bicarbonate, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine and glucose. Vital signs include body temperature, respiratory rate, pulse rate, supine systolic and diastolic blood pressure. CS=clinically significant, NCS=not clinically significant. Change from Screening to End of Study is reported.
Time frame: Measurements at screening and at study completion/termination are included in the analysis.
Pharmacokinetics: Incremental Recovery (IR) Over Time
PK infusion with investigational product was administered after a wash out period of at least 5 days. Incremental recovery is calculated as IR30min = (C30min \[IU/dL\] - Cpre-infusion \[IU/dL\]) / dose per kg body weight \[IU/kg\] where C30min and Cpre-infusion relate to the unadjusted concentration values.
Time frame: IR over time was measured as Baseline and at Completion/Termination visit within 30 minutes pre-infusion and at 30 (± 5) minutes post-infusion.
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞)
After a wash out period of at least 5 days PK infusion with investigational product was administered. AUC 0-∞ is defined as AUC 0-t + Ct/lambda z, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration.
Time frame: PK assessments were done within 30 minutes pre-infusion and post-infusion at 30 (± 5) minutes, 9 hours (± 30 minutes), 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours
Pharmacokinetics: Elimination Phase Half-life (T1/2)
PK infusion with investigational product was administered after a wash out period of at least 5 days. Elimination phase half-life is calculated as T1/2=log e (2) / lambda z where the elimination rate constant (lambda z) will be obtained by log e - linear fitting using least squares deviation to at least the last 3 quantifiable concentrations above pre-infusion level.
Time frame: PK assessments were done within 30 minutes pre-infusion and post-infusion at 30 (± 5) minutes, 9 hours (± 30 minutes), 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours
Pharmacokinetics: Mean Residence Time (MRT)
PK infusion with investigational product was administered after a wash out period of at least 5 days. Mean residence time is calculated as total area under the moment curve divided by the total area under the curve. MRT=(AUMC0-∞\[h2\*IU/dL\])/(AUC0-∞\[h\*IU/dL\]) - TI/2 where AUMC0-∞ is determined in a similar manner as AUC0-∞ and TI represents infusion duration in hours.
Time frame: PK assessments were done within 30 minutes pre-infusion and post-infusion at 30 (± 5) minutes, 9 hours (± 30 minutes), 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours
Pharmacokinetics: Systemic Clearance (CL)
PK infusion with investigational product was administered after a wash out period of at least 5 days. Systemic clearance is balculated as the dose in IU/kg divided by the total AUC. CL= Dose\[IU/kg\] / AUC0-∞\[h\*IU/dL\]
Time frame: PK assessments were done within 30 minutes pre-infusion and post-infusion at 30 (± 5) minutes, 9 hours (± 30 minutes), 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours
Pharmacokinetics: Volume of Distribution at Steady State (Vss)
PK infusion with investigational product was administered after a wash out period of at least 5 days. Apparent steady state volume of distribution is calculated as Vss = CL \* MRT CL=Systemic Clearance and MRT=Mean residence time
Time frame: PK assessments were done within 30 minutes pre-infusion and post-infusion at 30 (± 5) minutes, 9 hours (± 30 minutes), 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours
Pharmacokinetics: Incremental Recovery (IR)
PK infusion with investigational product was administered after a wash out period of at least 5 days. Incremental recovery is calculated as IR30min = (C30min \[IU/dL\] - Cpre-infusion \[IU/dL\]) / dose per kg body weight \[IU/kg\] where C30min and Cpre-infusion relate to the unadjusted concentration values.
Time frame: PK assessments were done within 30 minutes pre-infusion and post-infusion at 30 (± 5) minutes, 9 hours (± 30 minutes), 24 (± 2) hours, 48 (± 2) hours and 72 (± 2) hours.
Changes in Health Related Quality of Life (HR QoL) Based on Questionnaire SF-36
The Short Form (36) Health Survey (SF-36) is a 36-item validated, generic HR QoL instrument suitable for participants of 17 years of age or older. The SF-36 consists of eight scaled scores (vitality, physical functioning, bodily pain, general health, mental health, physical role functioning, emotional role functioning, social role functioning) which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. The mental health component summary score ranged from 19.5 to 64.2 with higher scores indicating less disability. The physical health component summary scores ranged from 18.6 to 59.6 with higher scores indicating less disability.
Time frame: Baseline at exposure day 1 and at study completion/termination.
Changes in Health Related Quality of Life Using the Peds QL
The Pediatric Quality of Life Inventory (Peds QL) is a generic health related quality of life instrument designed specifically for a pediatric population and captures following domains: physical functioning, emotional functioning, social functioning and school functioning. The Peds-QL total score consist of all 23 items of all domains. Score range from 0-100 and higher scores indicate better quality of life (collected scores ranged from 44.6 to 98.9). The Peds-QL Physical Health Summary score consists of 8 items from the physical functioning domain. Score range from 0-100 and higher scores indicate better quality of life (collected scores ranged from 40.6 to 100.0) The Psychosocial Health Summary score consists of 15 items from the emotional, social and school functioning domains. Score range from 0 to 100 and higher scores indicate better quality of life (collected scores ranged from 46.7 to 100.0).
Time frame: Baseline at exposure day 1 and at study completion/termination.
Changes in Health Related Quality of Life (HR QoL) Based on Questionnaire Haemo-QoL and Haem-A-QoL
The Hemophilia Quality of Life Questionnaire (Haemo-QoL) and the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-Qol) instruments have been developed and used in hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: physical health, sports/leisure, school/work, dealing with hemophilia, and outlook for the future. Haemo-QoL is used for participants aged 8 to 16 years and total scores range from 0 to 100 with higher scores indicating low quality of life (collected scores ranged from 0.0 to 44.3) Haem-A-QoL is used for participants aged 17 years and older and total scores range from 0 to 100 with higher scores indicating low quality of life (collected scores ranged from 4.9 to 76.8).
Time frame: Baseline at exposure day 1 and at study completion/termination.
Changes in Health Related Quality of Life (HR QoL) Based on Questionnaire EQ-5D and Pain Score.
The EQ-5D captures overall HR QoL (phyiscal, mental and social functioning). A health utility score can be calculated from this measure, adult and proxy versions available. EQ-5D Visual Analog Scale (EQ-5D VAS):Respondents specify their level of agreement to a statement by indicating a position along a continuous line between two endpoints (scale range from 0 to 100). Score 0 corresponds to the worst health you can imagine and score 100 corresponds to the best health you can imagine (collected scores ranged from 10-100). EQ-5D Total Index is based on general population valuation surveys. Responses to 5 questions are converted to an Index value and score range from 0 to 1, with higher scores indicating better quality of life. Total Index was derived on US population (collected scores ranged from 0.4-1). General pain assessment (Pain score) is done through a visual analog scale (VAS), scores ranging from 0 to 100 with higher scores indicating more pain (collected scores ranged 0-87).
Time frame: Baseline at exposure day 1 and at study completion/termination.
Enrollment was conducted at 40 clinical sites in 18 countries. A total of 117 participants were enrolled. Of these, 65 participants transitioned from BAX326 pivotal study, 20 participants transitioned from BAX326 pediatric study and 32 participants were newly recruited.
| Milestone | BAX 326 |
|---|---|
| Started | 115 |
| Completed | 96 |
| Not completed | 19 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Protocol violation | 5 |
| Withdrew: Physician decision | 2 |
| Withdrew: Participant had scheduled surgery | 1 |
| Withdrew: Participant moved to another country | 1 |
| Withdrew: Discontinued by sponsor | 1 |
Possibly or probably related adverse events that occurred during or after first BAX326 infusion.
| Adverse Events | BAX 326 |
|---|---|
| Adverse Events Possibly or Probably Related to the Investigational Product | 2 |
Number of Infusions of BAX326 that were required until bleed resolution.
| Number of infusions | BAX 326 | Standard Prophylaxis | Modified Prophylaxis | PK Tailored Prophylaxis | Overall Prophylaxis | On-Demand |
|---|---|---|---|---|---|---|
| Treatment of Bleeding Episodes: Number of Infusions Per Bleeding Episode Required Until Bleed Resolution | 1.8 ± 1.65 | 2.1 ± 2.12 | 1.9 ± 1.41 | 1.3 ± 0.46 | 2.0 ± 2.01 | 1.5 ± 0.79 |
Overall clinical efficacy rating of bleeding episodes was done at resolution of bleed according these rating scale: Excellent=Full relief of pain and cessation of objective signs of bleeding after a single infusion. No additional infusion is required for the control of bleeding. Administration of further infusion would not affect the scoring. Good=Definite pain relief and/or improvement in signs of bleeding after a single infusion. Possibly requires more than 1 infusion for complete resolution. Fair=Probable and/or slight relief of pain and slight improvement in signs of bleeding after a single infusion. Required more than 1 infusion for complete resolution. None=No improvement or condition worsens.
| Number of infusions | BAX 326 | Standard Prophylaxis | Modified Prophylaxis | PK Tailored Prophylaxis | Overall Prophylaxis | On-Demand |
|---|---|---|---|---|---|---|
| Excellent | 341 | 168 | 51 | 0 | 219 | 122 |
| Good | 650 | 281 | 40 | 0 | 321 | 329 |
| Fair | 115 | 90 | 17 | 6 | 113 | 2 |
| None | 6 | 3 | 0 | 2 | 5 | 1 |
Annualized bleed rate (ABR) was calculated as (number of bleeding episodes/observed treatment period in days)\*365.25
| Bleeds per year | Standard Prophylaxis | Modified Prophylaxis | PK Tailored Prophylaxis | Overall Prophylaxis |
|---|---|---|---|---|
| Annualized Bleed Rate During Prophylaxis Treatment | 1.3 (0.0 to 78.7) | 1.4 (0.0 to 34.6) | 1.9 (0.5 to 3.3) | 1.3 (0.0 to 52.2) |
The number of infusions consumed per month and per year for the prophylactic and on-demand treatment regimens.
| Number of infusions | Standard Prophylaxis | Modified Prophylaxis | PK Tailored Prophylaxis | Overall Prophylaxis | On-Demand |
|---|---|---|---|---|---|
| Number of infusions per month | 8.5 ± 1.25 | 10.8 ± 4.34 | 4.0 ± 0.60 | 8.4 ± 1.38 | 3.6 ± 2.44 |
| Number of infusions per year | 101.8 ± 15.03 | 130.2 ± 52.13 | 48.3 ± 7.23 | 101.1 ± 16.50 | 43.1 ± 29.28 |
The weight adjusted consumption of BAX 326 per month and per year for the prophylactic and on-demand treatment regimens.
| IU/kg | Standard Prophylaxis | Modified Prophylaxis | PK Tailored Prophylaxis | Overall Prophylaxis | On-Demand |
|---|---|---|---|---|---|
| Weight adjusted BAX 326 consumption per month | 462.3 ± 102.05 | 684.4 ± 337.70 | 250.9 ± 41.37 | 464.2 ± 111.46 | 199.8 ± 124.18 |
| Weight adjusted BAX 326 consumption per year | 5547.8 ± 1224.65 | 8212.4 ± 4052.36 | 3010.3 ± 496.44 | 5570.7 ± 1337.53 | 2397.4 ± 1490.22 |
The weight adjusted consumption of BAX 326 per bleeding episode for the prophylactic and on-demand treatment regimens. Only infusions required until the resolution of bleed are considered.
| IU/kg | Standard Prophylaxis | Modified Prophylaxis | PK Tailored Prophylaxis | Overall Prophylaxis | On-Demand |
|---|---|---|---|---|---|
| Consumption of BAX326: Weight Adjusted Consumption Per Bleeding Episode | 124.2 ± 140.70 | 114.8 ± 99.41 | 67.4 ± 34.39 | 122.0 ± 134.02 | 82.6 ± 48.21 |
Testing for inhibitory and total binding antibodies to Factor IX (FIX). Development during study means negative at screening and positive at any subsequent visit. Treatment emergent means more than 2-dilution increase as compared to the pre-study titer at screening.
| Participants | BAX 326 |
|---|---|
| Inhibitory antibodies to FIX-develop. during study | 0 |
| Inhibitory antibodies to FIX-treatment emergent | 0 |
| Total bind. antibodies to FIX-develop.during study | 0 |
| Total binding antibodies to FIX-treatment emergent | 0 |
Testing for antibodies to CHO proteins and rFurin. Development during study means negative at screening and positive at any subsequent visit. Treatment emergent means more than 2-dilution increase as compared to the pre-study titer at screening.
| Participants | BAX 326 |
|---|---|
| Antibodies to CHO - developed during study | 0 |
| Antibodies to CHO - treatment emergent | 0 |
| Antibodies to rFurin - developed during study | 4 |
| Antibodies to rFurin - treatment emergent | 4 |
The occurrence of severe allergic reactions and thrombotic events was assessed.
| Participants | BAX 326 |
|---|---|
| Severe allergic reactions | 0 |
| Thrombotic events | 0 |
Hematology panel consists of complete blood count (hemoglobin, hematocrit, erythrocytes, leukocytes) with differential (ie, basophils, eosinophils, lymphocytes, monocytes, neutrophils), mean corpuscular volume, mean corpuscular hemoglobin concentration and platelet count. Clinical chemistry panel consists of sodium, potassium, chloride, bicarbonate, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine and glucose. Vital signs include body temperature, respiratory rate, pulse rate, supine systolic and diastolic blood pressure. CS=clinically significant, NCS=not clinically significant. Change from Screening to End of Study is reported.
| Participants | BAX 326 |
|---|---|
| Hematology: Change from normal to abnormal CS | 2 |
| Hematology:Change from abnormal NCS to abnormal CS | 1 |
| Chemistry: Change from normal to abnormal, CS | 1 |
| Chemistry: Change from abnormal NCS to abnormal CS | 3 |
| Change in vital signs | 0 |
PK infusion with investigational product was administered after a wash out period of at least 5 days. Incremental recovery is calculated as IR30min = (C30min \[IU/dL\] - Cpre-infusion \[IU/dL\]) / dose per kg body weight \[IU/kg\] where C30min and Cpre-infusion relate to the unadjusted concentration values.
| (IU/dL):(IU/kg) | BAX 326 |
|---|---|
| Baseline | 0.85 ± 0.207 |
| End of Study | 0.85 ± 0.286 |
| Change from baseline to end of study | -0.005 ± 0.259 |
After a wash out period of at least 5 days PK infusion with investigational product was administered. AUC 0-∞ is defined as AUC 0-t + Ct/lambda z, where t is the time of last quantifiable concentration, Ct is the last quantifiable concentration.
| IU*hr/dL | BAX 326 |
|---|---|
| Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC 0-∞) | 1335.56 ± 299.83 |
PK infusion with investigational product was administered after a wash out period of at least 5 days. Elimination phase half-life is calculated as T1/2=log e (2) / lambda z where the elimination rate constant (lambda z) will be obtained by log e - linear fitting using least squares deviation to at least the last 3 quantifiable concentrations above pre-infusion level.
| hours | BAX 326 |
|---|---|
| Pharmacokinetics: Elimination Phase Half-life (T1/2) | 28.52 ± 4.12 |
PK infusion with investigational product was administered after a wash out period of at least 5 days. Mean residence time is calculated as total area under the moment curve divided by the total area under the curve. MRT=(AUMC0-∞\[h2\*IU/dL\])/(AUC0-∞\[h\*IU/dL\]) - TI/2 where AUMC0-∞ is determined in a similar manner as AUC0-∞ and TI represents infusion duration in hours.
| hours | BAX 326 |
|---|---|
| Pharmacokinetics: Mean Residence Time (MRT) | 29.97 ± 2.72 |
PK infusion with investigational product was administered after a wash out period of at least 5 days. Systemic clearance is balculated as the dose in IU/kg divided by the total AUC. CL= Dose\[IU/kg\] / AUC0-∞\[h\*IU/dL\]
| dL/kg/hours | BAX 326 |
|---|---|
| Pharmacokinetics: Systemic Clearance (CL) | 0.06 ± 0.014 |
PK infusion with investigational product was administered after a wash out period of at least 5 days. Apparent steady state volume of distribution is calculated as Vss = CL \* MRT CL=Systemic Clearance and MRT=Mean residence time
| dL/kg | BAX 326 |
|---|---|
| Pharmacokinetics: Volume of Distribution at Steady State (Vss) | 1.78 ± 0.42 |
PK infusion with investigational product was administered after a wash out period of at least 5 days. Incremental recovery is calculated as IR30min = (C30min \[IU/dL\] - Cpre-infusion \[IU/dL\]) / dose per kg body weight \[IU/kg\] where C30min and Cpre-infusion relate to the unadjusted concentration values.
| (IU/dL):(IU/kg) | BAX 326 |
|---|---|
| Pharmacokinetics: Incremental Recovery (IR) | 0.85 ± 0.196 |
The Short Form (36) Health Survey (SF-36) is a 36-item validated, generic HR QoL instrument suitable for participants of 17 years of age or older. The SF-36 consists of eight scaled scores (vitality, physical functioning, bodily pain, general health, mental health, physical role functioning, emotional role functioning, social role functioning) which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability. The mental health component summary score ranged from 19.5 to 64.2 with higher scores indicating less disability. The physical health component summary scores ranged from 18.6 to 59.6 with higher scores indicating less disability.
| Score on a scale | BAX 326 |
|---|---|
| SF-36 Bodily Pain | 6.7 ± 12.66 |
| SF-36 General Health | 3.2 ± 9.32 |
| SF-36 Mental Health | 0.7 ± 14.72 |
| SF-36 Mental Health Component Score | 0.8 ± 12.08 |
| SF-36 Physical Functioning | 4.2 ± 10.46 |
| SF-36 Physical Health Component Score | 5.7 ± 8.43 |
| SF-36 Role-Emotional | 2.3 ± 11.57 |
| SF-36 Role-Physical | 4.5 ± 10.28 |
| SF-36 Social Functioning | 4.5 ± 11.67 |
| SF-36 Vitality | 2.0 ± 8.87 |
The Pediatric Quality of Life Inventory (Peds QL) is a generic health related quality of life instrument designed specifically for a pediatric population and captures following domains: physical functioning, emotional functioning, social functioning and school functioning. The Peds-QL total score consist of all 23 items of all domains. Score range from 0-100 and higher scores indicate better quality of life (collected scores ranged from 44.6 to 98.9). The Peds-QL Physical Health Summary score consists of 8 items from the physical functioning domain. Score range from 0-100 and higher scores indicate better quality of life (collected scores ranged from 40.6 to 100.0) The Psychosocial Health Summary score consists of 15 items from the emotional, social and school functioning domains. Score range from 0 to 100 and higher scores indicate better quality of life (collected scores ranged from 46.7 to 100.0).
| Score on a scale | BAX 326 |
|---|---|
| Peds-QL Physical Health Summary Score | -2.3 ± 18.47 |
| Peds-QL Psychosocial Health Summary Score | 3.8 ± 5.99 |
| Peds-QL Total Score | 1.6 ± 10.14 |
The Hemophilia Quality of Life Questionnaire (Haemo-QoL) and the Hemophilia Quality of Life Questionnaire for Adults (Haem-A-Qol) instruments have been developed and used in hemophilia A patients. As a hemophilia-specific instrument, this measure assesses very specific aspects of dealing with hemophilia. The areas covered by this instrument are: physical health, sports/leisure, school/work, dealing with hemophilia, and outlook for the future. Haemo-QoL is used for participants aged 8 to 16 years and total scores range from 0 to 100 with higher scores indicating low quality of life (collected scores ranged from 0.0 to 44.3) Haem-A-QoL is used for participants aged 17 years and older and total scores range from 0 to 100 with higher scores indicating low quality of life (collected scores ranged from 4.9 to 76.8).
| Score on a scale | BAX 326 |
|---|---|
| Haem-A-QoL Total Score | -3.0 ± 9.45 |
| Haemo-QoL Total Score | -0.7 ± NA |
The EQ-5D captures overall HR QoL (phyiscal, mental and social functioning). A health utility score can be calculated from this measure, adult and proxy versions available. EQ-5D Visual Analog Scale (EQ-5D VAS):Respondents specify their level of agreement to a statement by indicating a position along a continuous line between two endpoints (scale range from 0 to 100). Score 0 corresponds to the worst health you can imagine and score 100 corresponds to the best health you can imagine (collected scores ranged from 10-100). EQ-5D Total Index is based on general population valuation surveys. Responses to 5 questions are converted to an Index value and score range from 0 to 1, with higher scores indicating better quality of life. Total Index was derived on US population (collected scores ranged from 0.4-1). General pain assessment (Pain score) is done through a visual analog scale (VAS), scores ranging from 0 to 100 with higher scores indicating more pain (collected scores ranged 0-87).
| Score on a scale | BAX 326 |
|---|---|
| EQ-5D Total Index | 0.0 ± 0.13 |
| EQ-5D VAS | 5.1 ± 21.75 |
| Pain Score | -8.0 ± 36.62 |
Collected over Throughout the entire study period from screening to completion/termination. Overall 6 years and 2 months. For each participant the duration of study depended on when the participant has accumulated a total of 100 exposure days during the course of the pivotal/pediatric studies and this study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BAX 326 | 0/115 (0%) | 9/115 (7.8%) | 63/115 (54.8%) |
| Event | BAX 326 |
|---|---|
| Renal colicRenal and urinary disorders | 2/115 |
| Abdominal painGastrointestinal disorders | 1/115 |
| Duodenal ulcer hemorrhageGastrointestinal disorders | 1/115 |
| Corneal abscessInfections and infestations | 1/115 |
| Brain contusionInjury, poisoning and procedural complications | 1/115 |
| Extradural hematomaInjury, poisoning and procedural complications | 1/115 |
| Head injuryInjury, poisoning and procedural complications | 1/115 |
| Scroctal haematomaInjury, poisoning and procedural complications | 1/115 |
| SeizureNervous system disorders | 1/115 |
| Transient ischaemic attackNervous system disorders | 1/115 |
| Event | BAX 326 |
|---|---|
| NasopharyngitisInfections and infestations | 25/115 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/115 |
| PyrexiaGeneral disorders | 14/115 |
| Upper respiratory tract infectionInfections and infestations | 11/115 |
| CoughRespiratory, thoracic and mediastinal disorders | 11/115 |
| InfluenzaInfections and infestations | 8/115 |
| RhinitisInfections and infestations | 8/115 |
| HeadacheNervous system disorders | 8/115 |
| BronchitisInfections and infestations | 6/115 |
| PharyngitisInfections and infestations | 6/115 |
| Age, Continuous(years) | BAX 326 |
|---|---|
| Mean | 29.6 ± 16.39 |
| Sex: Female, Male(Participants) | BAX 326 |
|---|---|
| Female | 0 |
| Male | 115 |
| Race/Ethnicity, Customized(Participants) | BAX 326 |
|---|---|
| Race — White | 99 |
| Race — Black or African American | 1 |
| Race — Asian | 10 |
| Race — Other | 5 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Baxalta now part of Shire